Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03144206 · ClinicalTrials.gov registry record · Phase 4
Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
A Phase 4 study of Sarcoma and Hyperbaric Oxygen Therapy, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03144206: Recruiting Phase 4 study of Sarcoma and Hyperbaric Oxygen Therapy, sponsored by Duke University.
NCT03144206 is a Phase 4 study of Sarcoma and Hyperbaric Oxygen Therapy that is actively recruiting participants, run by Duke University. The registered enrollment target is 20 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03144206, a Phase 4 study of Sarcoma and Hyperbaric Oxygen Therapy, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A parallel-group randomized pilot trial at a single institution (Duke University) on the effect of postoperative hyperbaric oxygen therapy on wound healing in patients with soft tissue sarcoma undergoing surgical resection with neo-adjuvant radiation therapy.. Participants will be allocated to either the treatment group (HBOT) or control (standard of care) by computer-generated randomization, stratified by tumor size (≤10cm and \>10cm). An unequal randomization of 2:1 will be utilized to provide experience prescribing HBOT to more patients.
Primary Outcome
The proportion of eligible patients who enroll in this study, as indicated by the screening log.
Conditions Studied
Interventions
- DRUG Hyperbaric oxygen
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT03144206 shows while recruiting
NCT03144206 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Hyperbaric oxygen is the first listed.
NCT03144206 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03144206 about?
NCT03144206 is a clinical study titled "Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study". A parallel-group randomized pilot trial at a single institution (Duke University) on the effect of postoperative hyperbaric oxygen therapy on wound healing in patients with soft tissue sarcoma undergoing surgical resection with neo-adjuvant radiation therapy.. Participants will be allocated to eithe...
What is the current status of trial NCT03144206?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2017-10-19. Estimated completion is 2026-12-31.
What conditions does trial NCT03144206 study?
This clinical trial studies the following conditions: Sarcoma, Hyperbaric Oxygen Therapy.
What interventions are being tested in trial NCT03144206?
The interventions under investigation include: Hyperbaric oxygen (DRUG).
Who is sponsoring clinical trial NCT03144206?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03144206 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03144206's enrollment target sits among peer trials
20 101st of 122 higher than 19 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®
ACTIVE NOT RECRUITING · Phase 4
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
RECRUITING
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy